The cologne stroke experience:: Safety and outcome in 450 patients treated with intravenous thrombolysis

被引:46
作者
Sobesky, Jan
Frackowiak, Monika
Weber, Olivier Zaro
Hahn, Moritz
Moeller-Hartmann, Walter
Rudolf, Jobst
Neveling, Michael
Grond, Martin
Schmulling, Susanne
Jacobs, Andreas
Heiss, Wolf-Dieter
机构
[1] Univ Cologne, Dept Neurol, Max Planck Inst Neurol Res, D-50924 Cologne, Germany
[2] Univ Cologne, Dept Diagnost Radiol, Cologne, Germany
[3] Univ Cologne, Dept Med Stat, Cologne, Germany
关键词
intravenous thrombolysis; modified Rankin scale; functional independence; stroke;
D O I
10.1159/000103117
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Predictors of outcome and safety in intravenous thrombolysis within 3 h in clinical routine is a matter of ongoing debate. Available reports contain small patient numbers or summarize heterogeneous multicenter data. Methods: Four hundred and fifty patients received intravenous thrombolysis within 3 h after stroke. Pretreatment NIHSS score and detailed medical history were analyzed. Noncontrast CT was performed before thrombolysis, 24-36 h later and in case of clinical deterioration. Symptomatic intracranial hemorrhage (SICH; any bleeding with an NIHSS increase of >= 4 points) and clinical outcome (modified Rankin Scale, mRS) after 3 months were recorded. Logistic regression identified parameters predictive of independence (mRS 0 - 2) and SICH. Results: Median onset to admission, door to needle and onset to treatment time was 75, 50 and 135 min, respectively. Direct presentation by emergency service (64%) was the fastest way of referral. Median pretreatment NIHSS was 11 points. Independence (mRS 0-2) was reached by 53%. Mortality was 11% (7% intracerebral, 4% extracerebral complications). Logistic regression identified low NIHSS, low age and absent diabetes as predictors of independence. Overall hemorrhagic complications and SICH were found in 18 and 4% of the patients, respectively. Extracerebral bleeding complications and allergic reactions were found in 3 and 1%, respectively. Conclusion: This largest single center report presents a sample in the range of the 3 h rt-PA cohort of all randomized controlled trials. Outcome was comparable to randomized studies with a higher rate of independence and a lower rate of mortality and SICH. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:56 / 65
页数:10
相关论文
共 28 条
[1]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[2]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[3]   Thrombolysis in stroke patients aged 80 years and older:: Swiss survey of IV thrombolysis [J].
Engelter, ST ;
Reichhart, M ;
Sekoranja, L ;
Georgiadis, D ;
Baumann, A ;
Weder, B ;
Müller, F ;
Lüthy, R ;
Arnold, M ;
Michel, P ;
Mattle, HP ;
Tettenborn, B ;
Hungerbühler, HJ ;
Baumgartner, RW ;
Sztajzel, R ;
Bogousslavsky, J ;
Lyrer, PA .
NEUROLOGY, 2005, 65 (11) :1795-1798
[4]   Early intravenous thrombolysis for acute ischemic stroke in a community-based approach [J].
Grond, M ;
Stenzel, C ;
Schmülling, S ;
Rudolf, J ;
Neveling, M ;
Lechleuthner, A ;
Schneweis, S ;
Heiss, WD .
STROKE, 1998, 29 (08) :1544-1549
[5]   Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000 [J].
Grotta, JC ;
Burgin, WS ;
El-Mitwalli, A ;
Long, M ;
Campbell, M ;
Morgenstern, LB ;
Malkoff, M ;
Alexandrov, AV .
ARCHIVES OF NEUROLOGY, 2001, 58 (12) :2009-2013
[6]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[7]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[8]  
Hacke W, 2004, LANCET, V363, P768
[9]  
HILL MD, 2000, CMAJ, V172, P1307
[10]   Diabetes: Impact on stroke risk and poststroke recovery [J].
Kissela, Brett ;
Air, Ellen .
SEMINARS IN NEUROLOGY, 2006, 26 (01) :100-107